Skip to main content
SpringerLink
Log in

Langdurig overleven na een behandeling voor testiskanker

  • Artikelen
  • Published:
Bijblijven

Samenvatting

Een kiemceltumor van de testis is een zeldzame vorm van kanker, hoewel het onder mannen van 20-35 jaar de meest voorkomende vorm van kanker is. Op basis van de initiële orchidectomie wordt de histologische diagnose seminoom of non-seminoom gesteld, waarna stadiëring volgt met CT-scan en tumormarkers. Bij patiënten met een tot de testis beperkt non-seminoom volstaat nauwgezette follow-up. Bij gelokaliseerde seminomen volgt na de orchidectomie vaak nog para-iliacale radiotherapie. Is er sprake van gemetastaseerde ziekte, dan worden na de orchidectomie drie of vier kuren combinatiechemotherapie met cisplatine gegeven.

Met een overallkans op genezing van 95% (80% voor gemetastaseerde ziekte) staat testiskanker model voor een vorm van kanker die te genezen is door een optimale combinatie van chemotherapie, radiotherapie en chirurgie. Ook na een succesvolle behandeling echter moet men in de follow-up alert blijven op eventuele langetermijnmorbiditeit, in de vorm van contralaterale testiskanker, late recidieven, secundaire tumoren, infertiliteit, hypertensie, hypercholesterolemie, metabool syndroom en hart- en vaatziekte. Verder onderzoek is noodzakelijk om de pathogenese van late effecten beter te begrijpen en zo de kans op het ontstaan ervan te minimaliseren.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. Dearnaley DP, Huddart RA, Horwich A. Managing testicular cancer. Br Med J 2001;322:1583-8.

    Google Scholar 

  2. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.

    Google Scholar 

  3. Mead GM. Who should manage germ cell tumours of the testis. BJU Int 1999;89:61-7.

    Google Scholar 

  4. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, Wit R de, et al. Impact of the treating institution on survival of patients with ‘poor-prognosis’ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91:839-46.

    Google Scholar 

  5. Wit R de, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006;24:5482-92.

    Google Scholar 

  6. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299:672-84.

    Google Scholar 

  7. ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of mixed non-seminomatous germ cell tumours (NSGCT). Ann Oncol 2001;12:1215-6.

  8. ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of testicular seminoma. Ann Oncol 2001;12:1217-8.

    Google Scholar 

  9. Baniel J, Foster RS, Gonin R, Messemeer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.

    Google Scholar 

  10. Bokemeyer C, Berger, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-32.

  11. Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002;13:229-36.

    Google Scholar 

  12. Nuver J, Smit AJ, Meer J van der, Berg MP van den, Graaf WT van der, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005;23:9130-7.

    Google Scholar 

  13. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchidectomy in men with testicular cancer. J Clin Oncol 1999;17:941-7.

    Google Scholar 

  14. Travis LB, Curtis RE, Storm H, Holowaty E, Leeuwen FE van, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.

    Google Scholar 

  15. Travis LB, Fossa SD, Shonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40.576 testicular cancer patients: focus of long-term survivors. J Natl Cancer Inst 2005;97:1354-65.

    Google Scholar 

  16. Belt-Dusebout AW van den, Wit R de, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risk of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-8.

    Google Scholar 

  17. Travis LB, Andersson M, Gospodarowicz M, Leeuwen FE van, Bergfeldt K, Lynch CF, et al. Treatment associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.

    Google Scholar 

  18. Fossa SD, Chen J, Shonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: A population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-66.

    Google Scholar 

  19. Meinardi MT, Gietema JA, Graaf WTA van der, Veldhuisen DJ van, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32.

    Google Scholar 

  20. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23.

    Google Scholar 

  21. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure for testicular seminoma. J Clin Oncol 2004; 22:640-7.

    Google Scholar 

  22. Belt-Dusebout AW van den, Nuver J, Wit R de, Gietema JA, Bokkel Huinink WW ten, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-75.

    Google Scholar 

  23. Nuver J, Smit AJ, Sleijfer DTh, Gessel AI van, Roon AM van, Meer J van der, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40:701-6.

  24. Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718-25.

    Google Scholar 

  25. Haughnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18:241-48.

    Google Scholar 

  26. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med 2002;136:463-70.

    Google Scholar 

  27. Haas EC de, Sleijfer DTh, Gietema JA. Follow-up of succesfully treated patients: consequences of the metabolic syndrome. Ann Oncol 2007;18: 211-2.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bijblijven.bsl.nl

    J. A. Gietema

Authors
  1. J. A. Gietema
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

internist-oncoloog, Afdeling Interne Geneeskunde, Onderafdeling Medische Oncologie, Universitair Medisch Centrum Groningen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gietema, J.A. Langdurig overleven na een behandeling voor testiskanker. BIJB 24, 38–44 (2008). https://doi.org/10.1007/BF03076346

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03076346

Keywords

Search

Navigation